■Growth Strategy
1. Mid-Term Management Plan 2026
Pharma Foods ＜2929＞ has set “New Value Creation 1K” in the “Mid-Term Management Plan 2026” (2022/7 to 2026/7), and is aiming for sales of 100 billion yen in the 2026/7 fiscal year through efforts to create new value (new products, new markets, new organizations). The breakdown of numerical sales targets is 70 billion yen for growth in existing businesses, 30 billion yen for new value creation, an average sales growth rate of 20% or more by the 2026/7 fiscal year as commitments, and a total return ratio of 20%, including treasury stock acquisitions. Regarding profit levels, we aim to build a system that can secure an average operating profit margin of 10% by developing businesses without fear of a decline in profit margins in a single year until the 2026/7 fiscal year, and boldly expanding the scale while taking risks.
NB products from the BtoB business and new products from the BtoC business have grown
2. New product creation
To create new products following “Pharma Gaba (R),” “Pneumo (R) hair growth agents,” etc., we will promote research and development such as development of new materials, development of new uses and effects, and development of next-generation antibodies. In addition, we will also promote product development in the Scalp & Skin field, pharmaceutical mail order, and oral care fields. In 2021/7, a sales agreement was signed with Mitsui Sugar Co., Ltd., of the DM Mitsui Sugar Holdings ＜2109＞ Group for the functional food ingredient “Lipismart (R),” which suppresses absorption of triglycerides. By developing a unique technology (patent pending) to manufacture “Lipismart (R)” from “sesame” through joint development with Mitsui Sugar, it first entered the metabolic market. Furthermore, NB products from the BtoB business and new products from the BtoC business are growing, and we are planning to develop and launch a total of 50 or more new products (23 companies, 20 Future Labs, 16 Meiji Pharmaceutical, etc.) over the next 2 years.
(Author: FISCO Visiting Analyst Masashi Mizuta Exhibition)